Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma

BACKGROUND: Patients with multiple myeloma (MM) were excluded from the original SARS-CoV-2 mRNA vaccine trials, which may influence vaccine hesitancy in this population. We prospectively characterized the safety and immunogenicity of two-dose SARS-CoV-2 mRNA vaccination in 44 patients with MM, who u...

Descripción completa

Detalles Bibliográficos
Autores principales: Greenberg, Ross S., Ruddy, Jake A., Boyarsky, Brian J., Werbel, William A., Garonzik-Wang, Jacqueline M., Segev, Dorry L., Imus, Philip H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8711688/
https://www.ncbi.nlm.nih.gov/pubmed/34961488
http://dx.doi.org/10.1186/s12885-021-09097-5
Descripción
Sumario:BACKGROUND: Patients with multiple myeloma (MM) were excluded from the original SARS-CoV-2 mRNA vaccine trials, which may influence vaccine hesitancy in this population. We prospectively characterized the safety and immunogenicity of two-dose SARS-CoV-2 mRNA vaccination in 44 patients with MM, who underwent vaccination from 12/17/2020 to 3/18/2021. RESULTS: Rates adverse reactions were low and consistent with those documented in vaccine trials. Among those on MM therapy, 93% developed detectable anti-receptor binding domain (RBD) antibodies after dose 2, while 94% of patients not on MM therapy seroconverted. CONCLUSIONS: Two-dose SARS-CoV-2 mRNA vaccination is mildly reactogenic and leads to high rates of seroconversion in patients with MM. These findings can provide reassurance to MM patients who are hesitant to receive SARS-CoV-2 mRNA vaccines. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-09097-5.

Ejemplares similares